Drug Wholesaling Hits $1.3T as Big Three Tighten Iron Grip

The pharmaceutical supply chain has become a titan of American commerce. The drug wholesaling industry hit $1.32 trillion in 2026 revenue, according to IBISWorld data, representing steady growth from $1.4 trillion the previous year as the sector continues its modest 1.0% compound annual growth rate since 2020. Yet beneath this massive figure lies a stark reality: the industry is dominated by three companies to a degree rarely seen in any American market. McKesson Corporation leads the pack with $359.1 billion in fiscal 2025 revenue, up 16% year-over-year, with its U.S. pharmaceutical segment alone accounting for $327.7 billion. Cencara (formerly AmerisourceBergen) generated $321.3 billion in the same period, while Cardinal Health posted $222.6 billion—a slight decline due to an expired major customer contract, though underlying growth excluding that loss reached approximately 18%. Together, these three wholesalers account for roughly $900 billion in combined annual revenue, controlling over 90% of the entire U.S. drug distribution market. This concentration is historically unprecedented in the pharmaceutical supply chain and ranks among the highest of any American industry. The consolidation reflects decades of mergers and acquisitions that have eliminated smaller competitors and reshaped how medications reach pharmacies, hospitals and patients across the country. The three giants handle everything from brand-name prescription drugs to generics and nutritional supplements—the largest segment of the wholesaling market. Margins have tightened despite growing sales volumes. Since 2015, total gross profit dollars at the Big Three have declined even as their revenues climbed, compressed by generic drug deflation and diminishing opioid volumes that once buoyed returns. Specialty drugs and increased pharmaceutical volumes have driven top-line growth, but the economics of scale and competitive pricing have limited profitability gains. The industry encompasses 9,419 businesses in total, down from higher levels in prior years as smaller distributors struggle to compete against the dominant trio. The wholesaling industry's trajectory reflects broader dynamics reshaping American healthcare. As drug prices climb and supply chain complexity deepens, power concentrates further among the few companies capable of managing billions of units of medicine annually. For hospitals, pharmacies and regulators, the three-company duopoly presents both efficiency and risk—a critical chokepoint through which the nation's pharmaceutical supply flows.